• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊曲康唑纳米混悬剂的下游药物产品加工:影响压片纳米混悬层糖珠材料性质和溶出的因素。

Downstream drug product processing of itraconazole nanosuspension: Factors influencing tablet material properties and dissolution of compacted nanosuspension-layered sugar beads.

机构信息

AbbVie Pte Ltd, Research and Development, 9 North Buona Vista Drive, The Metropolis Tower One #19-01, Singapore 138588, Singapore.

Gustav Parmentier GmbH, Eichendorffstr. 37, 60320 Frankfurt am Main, Germany.

出版信息

Int J Pharm. 2017 Oct 30;532(1):131-138. doi: 10.1016/j.ijpharm.2017.08.107. Epub 2017 Aug 30.

DOI:10.1016/j.ijpharm.2017.08.107
PMID:28859940
Abstract

There has been limited research done on the downstream processing of nanosuspensions into solid oral dosage forms. This paper demonstrates the bead layering process with a layering level at 150% and 240%, as well as the selection and justification of the outer phase excipients for tabletability and disintegrating properties. In a previous study, an itraconazole nanosuspension stabilised by SDS and HPMC E5 was layered onto sugar beads with coating polymer HPMC VLV. In the current study, compression studies with these layered beads utilising the small bead size at 150% or 240% layering levels with outer phase cushioning excipients MCC, copovidone or isomalt were performed. Other excipients such as co-compressed crospovidone-PEG 4000; DCP functioning as a disintegrant; and HPC as a binder was also added. Target output variables were achieved with a balance between an adequate tensile strength and fast dissolution rate with a release of 99.0% (±1.0% SD) within 10min, which is in accordance with the FDA guidance for dissolution testing. The results show that the compaction of nanosuspension-layered beads is a suitable process for processing an itraconazole nanosuspension into a solid dosage form such as a compacted tablet without compromising on drug release.

摘要

对于将纳米混悬剂加工成固体口服剂型的下游处理,研究还很有限。本文展示了采用 150%和 240%的包衣水平的珠层工艺,以及选择和证明了外层辅料的可压性和崩解性能。在之前的研究中,用 SDS 和 HPMC E5 稳定的伊曲康唑纳米混悬液被包衣到 HPMC VLV 包衣聚合物的糖珠上。在当前的研究中,利用 150%或 240%包衣水平的小珠尺寸以及外层缓冲辅料 MCC、共聚维酮或异麦芽酮醇,对这些包衣珠进行了压缩研究。还添加了其他辅料,如共压缩的交联聚维酮-PEG4000;作为崩解剂的 DCP;以及作为粘合剂的 HPC。目标输出变量是通过在足够的拉伸强度和快速溶解速率之间取得平衡来实现的,在 10 分钟内释放 99.0%(±1.0%SD),这符合 FDA 对溶解试验的指导原则。结果表明,纳米混悬剂包衣珠的压缩是将伊曲康唑纳米混悬剂加工成固体剂型(如压片)的一种合适工艺,而不会影响药物释放。

相似文献

1
Downstream drug product processing of itraconazole nanosuspension: Factors influencing tablet material properties and dissolution of compacted nanosuspension-layered sugar beads.伊曲康唑纳米混悬剂的下游药物产品加工:影响压片纳米混悬层糖珠材料性质和溶出的因素。
Int J Pharm. 2017 Oct 30;532(1):131-138. doi: 10.1016/j.ijpharm.2017.08.107. Epub 2017 Aug 30.
2
Downstream drug product processing of itraconazole nanosuspension: Factors influencing drug particle size and dissolution from nanosuspension-layered beads.伊曲康唑纳米混悬液的下游药物产品加工:影响纳米混悬液层状微丸中药物粒径和溶出度的因素
Int J Pharm. 2017 May 30;524(1-2):443-453. doi: 10.1016/j.ijpharm.2017.04.012. Epub 2017 Apr 8.
3
Incorporation of itraconazole nano-co-crystals into multiparticulate oral dosage forms.将伊曲康唑纳米共晶纳入多颗粒口服剂型。
Eur J Pharm Biopharm. 2022 Jul;176:75-86. doi: 10.1016/j.ejpb.2022.05.011. Epub 2022 May 19.
4
Formulation and drying of miconazole and itraconazole nanosuspensions.米康唑和伊曲康唑纳米混悬剂的制备和干燥。
Int J Pharm. 2013 Feb 25;443(1-2):209-20. doi: 10.1016/j.ijpharm.2012.11.044. Epub 2013 Jan 4.
5
Effects of Surfactants on Itraconazole-Hydroxypropyl Methylcellulose Acetate Succinate Solid Dispersion Prepared by Hot Melt Extrusion III: Tableting of Extrudates and Drug Release From Tablets.热熔挤出制备的伊曲康唑-羟丙甲纤维素醋酸琥珀酸酯固体分散体中表面活性剂的影响 III:挤出物的压片和片剂的药物释放。
J Pharm Sci. 2019 Dec;108(12):3859-3869. doi: 10.1016/j.xphs.2019.09.014. Epub 2019 Sep 19.
6
Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach.采用质量源于设计方法通过热熔挤出制备无定形固体分散体片剂配方的研究
AAPS PharmSciTech. 2016 Feb;17(1):214-32. doi: 10.1208/s12249-015-0472-0. Epub 2016 Jan 12.
7
Formulation and performance of Irbesartan nanocrystalline suspension and granulated or bead-layered dried powders - Part I.厄贝沙坦纳米混悬剂和颗粒状或珠层状干粉末的配方和性能 - 第一部分。
Int J Pharm. 2019 Sep 10;568:118189. doi: 10.1016/j.ijpharm.2019.03.007. Epub 2019 Mar 6.
8
Downstream processing of irbesartan nanocrystalline suspension and mini-tablet development - Part II.阿替洛尔纳米混悬液的下游处理和迷你片剂的开发-第二部分。
Int J Pharm. 2019 Sep 10;568:118509. doi: 10.1016/j.ijpharm.2019.118509. Epub 2019 Jul 10.
9
Formulating Amorphous Solid Dispersions: Impact of Inorganic Salts on Drug Release from Tablets Containing Itraconazole-HPMC Extrudate.无定形固体分散体的制定:无机盐对含伊曲康唑-HPMC 挤出物片剂中药物释放的影响。
Mol Pharm. 2020 Aug 3;17(8):2768-2778. doi: 10.1021/acs.molpharmaceut.9b01109. Epub 2020 Jul 21.
10
Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.稳定剂对杨梅素纳米混悬液形成及其特性的影响:体外和体内评价
Int J Pharm. 2014 Dec 30;477(1-2):251-60. doi: 10.1016/j.ijpharm.2014.10.044. Epub 2014 Oct 18.

引用本文的文献

1
Transformation of ABT-199 Nanocrystal Suspensions into a Redispersible Drug Product-Impact of Vacuum Drum Drying, Spray Drying and Tableting on Re-Nanodispersibility.ABT-199纳米晶体悬浮液向可再分散药物产品的转化——真空转鼓干燥、喷雾干燥和压片对再纳米分散性的影响
Pharmaceutics. 2024 Jun 8;16(6):782. doi: 10.3390/pharmaceutics16060782.
2
The Increased Dissolution and Oral Absorption of Itraconazole by Nanocrystals with an Endogenous Small-Molecule Surfactant as a Stabilizer.以内源性小分子表面活性剂为稳定剂的纳米晶体提高伊曲康唑的溶出度和口服吸收
Molecules. 2024 Apr 13;29(8):1769. doi: 10.3390/molecules29081769.
3
Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability.
难溶性药物的纳米晶体:药物生物利用度与物理化学稳定性
Pharmaceutics. 2018 Aug 21;10(3):134. doi: 10.3390/pharmaceutics10030134.